Daewoong Pharmaceutical Reports More Than 90% Target Occupancy in Phase 1 Trial of Autoimmune Disease Drug
AI 요약 정보
- Plodicitinib tops 90% maximum BTK and ITK occupancy
- In 44 healthy adults, no serious events; all events mild
- Daewoong's MAD study aims to complete Phase 1 in Q1 2027